Mesoblast hits 300-patient target in Phase 3 back pain trial
Mesoblast has reached the enrolment target of at least 300 treated patients in its MSB-DR004 pivotal Phase 3 trial, evaluating rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease (DDD). The milestone means the randomised, placebo-controlled study is now powered to detect a statistically significant difference in pain reduction at its 12-month primary endpoint. Top-line results are expected in mid-2027, after the last enrolled patient completes follow-up.
Rexlemestrocel-L is an allogeneic, off-the-shelf stromal cell product delivered via a single intra-discal injection in combination with hyaluronic acid. The candidate carries FDA Regenerative Medicine Advanced Therapy (RMAT) designation, which confers the benefits of both Breakthrough and Fast Track status, including rolling review and priority review eligibility on filing of a Biologics Licence Application (BLA). Mesoblast said commercial manufacturing is proceeding in parallel with the trial, with the aim of filing for approval as soon as possible after results readout.
Clinical background and trial design
The MSB-DR004 trial is a confirmatory study building on MSB-DR003, Mesoblast's earlier Phase 3 programme, which met the same 12-month pain-reduction primary endpoint. The FDA has previously agreed on the trial design and accepted pain reduction as an approvable indication. Secondary endpoints include improvements in functional status, quality of life, and cessation of pain medication, with opioid discontinuation a particular focus. The company noted that discogenic back pain accounts for approximately 50% of prescription opioid use in the United States, giving the indication a public-health dimension beyond its commercial potential.
Chief executive Silviu Itescu said the enrolment milestone ensures "the trial is well powered for success" and that the company intends to file for approval as quickly as possible once results are available.
Market context and competitive landscape
CLBP associated with DDD represents a large and largely unmet clinical need. Mesoblast cites a US prevalence of more than seven million patients and projects peak-year revenues exceeding US$10 billion at single-digit market penetration. Those figures, sourced from commercial assessments dating to 2014 and 2015, should be treated as indicative rather than current consensus estimates.
The CLBP treatment landscape is crowded with interventional and pharmacological options, but regenerative approaches targeting the underlying disc pathology remain early-stage across the industry. Rexlemestrocel-L's RMAT designation and the FDA-agreed trial design give Mesoblast a relatively clear regulatory path, though approval in a pain indication will depend heavily on the magnitude and durability of the pain-reduction effect and on the safety profile in the full 300-patient dataset. Investors will also watch for any subgroup analysis in patients receiving opioids, given the company's emphasis on that cohort.
Mesoblast already holds an FDA-approved mesenchymal stromal cell therapy in the form of Ryoncil (remestemcel-L) for steroid-refractory acute graft-versus-host disease in paediatric patients, giving the company a degree of regulatory and commercial infrastructure on which to build a second product launch. The company has partnerships in Japan, Europe and China and is listed on both the Nasdaq and the Australian Securities Exchange.
With a mid-2027 readout horizon, the key near-term catalysts will be any interim safety disclosures, updates on manufacturing readiness, and potential partnering activity for major Western markets ahead of a BLA submission.